Cell-cycle arrest biomarkers: The light at the end of the acute kidney injury tunnel

Nephrology Dialysis Transplantation

Volumn 31, Issue 1, 2016, Pages 3-5

  Ronco, Claudio ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ARTICLE; CELL CYCLE ARREST; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MEDICAL DECISION MAKING; OLIGURIA; PATIENT CARE; POINT OF CARE TESTING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAPID TEST; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; ANIMAL; CELL CYCLE CHECKPOINT; PATHOLOGY;

ACUTE KIDNEY INJURY; ANIMALS; CELL CYCLE CHECKPOINTS; HUMANS;

EID: 84960087155     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv323     Document Type: Article

References (13)

1. Chawla L, Kimmel P. Acute kidney injury and chronic kidney disease. Kidney Int 2012; 82: 516-524
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
3. Cruz D, Bagshaw S, Maisel A, et al. Use of biomarkers to assess prognosis and guide management of patients with acute kidney injury. Contrib Nephrol 2013; 182: 45-64
4. Bihorac A, Yavas S, Subbiah S, et al. Long-Term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg 2009; 249: 851-858
5. U.S. Food and Drug Administration. FDA allows marketing of the first test to assess risk of developing acute kidney injury [Press release]. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm 412910.htm
6. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013; 17: R25
7. Hoste EA, McCullough PA, Kashani K, et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transplant 2014; 29: 2054-2081
8. Bihorac A, Chawla LS, Shaw AD, et al.Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014; 189: 932-939
9. BioMerieux. bioMerieux and Astute Medical sign a global agreement to develop and market NephroCheck® Test for VIDAS®, an assay to assess the risk of developing acute kidney injury [Press release]. 2014. http://www. biomerieux.com/en/biomerieux-And-Astute-medical-sign-global-Agreementdevelop-And-market-nephrocheckr-Test-vidasr
10. McCullough PA, Bouchard J, Waikar SS, et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 5-12
11. Ronco C, Kellum JA, Haase M. Subclinical AKI is still AKI. Crit Care 2012; 16: 313
12. Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract 2014; 127: 94-100
13. Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant 2016; 31: 16-22